213 related articles for article (PubMed ID: 24383913)
1. Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's β-amyloid peptides.
Fantini J; Di Scala C; Yahi N; Troadec JD; Sadelli K; Chahinian H; Garmy N
ACS Chem Neurosci; 2014 Mar; 5(3):216-24. PubMed ID: 24383913
[TBL] [Abstract][Full Text] [Related]
2. Interaction of Alzheimer's β-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation.
Di Scala C; Chahinian H; Yahi N; Garmy N; Fantini J
Biochemistry; 2014 Jul; 53(28):4489-502. PubMed ID: 25000142
[TBL] [Abstract][Full Text] [Related]
3. Bexarotene Does Not Clear Amyloid Beta Plaques but Delays Fibril Growth: Molecular Mechanisms.
Huy PDQ; Thai NQ; Bednarikova Z; Phuc LH; Linh HQ; Gazova Z; Li MS
ACS Chem Neurosci; 2017 Sep; 8(9):1960-1969. PubMed ID: 28689412
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β-amyloid peptide.
Di Scala C; Troadec JD; Lelièvre C; Garmy N; Fantini J; Chahinian H
J Neurochem; 2014 Jan; 128(1):186-95. PubMed ID: 23919567
[TBL] [Abstract][Full Text] [Related]
5. Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier.
Kuntz M; Candela P; Saint-Pol J; Lamartinière Y; Boucau MC; Sevin E; Fenart L; Gosselet F
J Alzheimers Dis; 2015; 48(3):849-62. PubMed ID: 26402114
[TBL] [Abstract][Full Text] [Related]
6. Structure of amyloid β
Kandel N; Matos JO; Tatulian SA
Sci Rep; 2019 Feb; 9(1):2689. PubMed ID: 30804528
[TBL] [Abstract][Full Text] [Related]
7. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides.
Di Scala C; Yahi N; Flores A; Boutemeur S; Kourdougli N; Chahinian H; Fantini J
Biochim Biophys Acta; 2016 Feb; 1862(2):213-22. PubMed ID: 26655601
[TBL] [Abstract][Full Text] [Related]
8. Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study.
Mirza Z; Beg MA
Curr Alzheimer Res; 2017; 14(3):327-334. PubMed ID: 27842487
[TBL] [Abstract][Full Text] [Related]
9. The inhibitory mechanism of a fullerene derivative against amyloid-β peptide aggregation: an atomistic simulation study.
Sun Y; Qian Z; Wei G
Phys Chem Chem Phys; 2016 May; 18(18):12582-91. PubMed ID: 27091578
[TBL] [Abstract][Full Text] [Related]
10. An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease.
Habchi J; Arosio P; Perni M; Costa AR; Yagi-Utsumi M; Joshi P; Chia S; Cohen SI; Müller MB; Linse S; Nollen EA; Dobson CM; Knowles TP; Vendruscolo M
Sci Adv; 2016 Feb; 2(2):e1501244. PubMed ID: 26933687
[TBL] [Abstract][Full Text] [Related]
11. How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40).
Yahi N; Aulas A; Fantini J
PLoS One; 2010 Feb; 5(2):e9079. PubMed ID: 20140095
[TBL] [Abstract][Full Text] [Related]
12. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity.
Bhatia R; Lin H; Lal R
FASEB J; 2000 Jun; 14(9):1233-43. PubMed ID: 10834945
[TBL] [Abstract][Full Text] [Related]
13. Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico.
Rosenthal J; Belfort G; Isaacson D
PLoS One; 2016; 11(4):e0153150. PubMed ID: 27073866
[TBL] [Abstract][Full Text] [Related]
14. Biochemical identification of a linear cholesterol-binding domain within Alzheimer's β amyloid peptide.
Di Scala C; Yahi N; Lelièvre C; Garmy N; Chahinian H; Fantini J
ACS Chem Neurosci; 2013 Mar; 4(3):509-17. PubMed ID: 23509984
[TBL] [Abstract][Full Text] [Related]
15. Norepinephrine Inhibits Alzheimer's Amyloid-β Peptide Aggregation and Destabilizes Amyloid-β Protofibrils: A Molecular Dynamics Simulation Study.
Zou Y; Qian Z; Chen Y; Qian H; Wei G; Zhang Q
ACS Chem Neurosci; 2019 Mar; 10(3):1585-1594. PubMed ID: 30605312
[TBL] [Abstract][Full Text] [Related]
16. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.
Corona AW; Kodoma N; Casali BT; Landreth GE
J Neuroimmune Pharmacol; 2016 Mar; 11(1):61-72. PubMed ID: 26175148
[TBL] [Abstract][Full Text] [Related]
17. The potential inhibitory effect of β-casein on the aggregation and deposition of Aβ
Hojati S; Ghahghaei A; Lagzian M
J Biomol Struct Dyn; 2018 Jun; 36(8):2118-2130. PubMed ID: 28633568
[TBL] [Abstract][Full Text] [Related]
18. Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and α-synuclein.
Di Scala C; Yahi N; Boutemeur S; Flores A; Rodriguez L; Chahinian H; Fantini J
Sci Rep; 2016 Jun; 6():28781. PubMed ID: 27352802
[TBL] [Abstract][Full Text] [Related]
19. Bexarotene cannot reduce amyloid beta plaques through inhibition of production of amyloid beta peptides: in silico and in vitro study.
Pham HDQ; Thai NQ; Bednarikova Z; Linh HQ; Gazova Z; Li MS
Phys Chem Chem Phys; 2018 Sep; 20(37):24329-24338. PubMed ID: 30211407
[TBL] [Abstract][Full Text] [Related]
20. The active role of Ca
Sciacca MFM; Monaco I; La Rosa C; Milardi D
Chem Commun (Camb); 2018 Apr; 54(29):3629-3631. PubMed ID: 29577161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
